Showing 7531-7540 of 9822 results for "".
- Closing Gaps: Takeda Enhances Diversity in Psoriasis Trialshttps://practicaldermatology.com/news/closing-gaps-takeda-enhances-diversity-in-psoriasis-trials/2471442/Takeda’s phase 3 psoriasis (PsO) clinical trials in the United States achieved success in enhancing racial and ethnic diversity among participants, according to new data from the manufacturer. Psoriasis affects over 7.5 millio
- Analysis: Nicotinamide Not Linked to Elevated MACE Riskhttps://practicaldermatology.com/news/study-nicotinamide-not-linked-to-mace-risk/2471380/Results from a new retrospective cohort study suggest nicotinamide exposure was not associated with an increased risk of major adverse cardiovascular events (MACE). The analysis included data from 13,108 patients in the Vanderb
- Cardio-Dermatology: Multidisciplinary Care Essential for Reducing Multifaceted Riskhttps://practicaldermatology.com/news/cardio-dermatology-multidisciplinary-care-essential-for-reducing-multifaceted-risk/2471287/Chronic skin conditions like psoriasis and atopic dermatitis (AD) are more than skin-deep—they carry significant risks for heart disease and require special attention, according to a compelling presentation given at Masterclasses in Dermatology 2025 in Sarasota. In her talk, Brittany Weber
- Bill Collection Made Tougher by Recent Changes in Credit Reportinghttps://practicaldermatology.com/news/Bill-Collection-Made-Tougher-Recent-Changes-Credit-Reporting/2471259/Americans owe $220 billion in medical debt,1 and the most effective method for collecting money could soon cease to be an option. Mark Nestor, MD, PhD, highlighted this issue during a presentation at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “Ba
- Patient-Centric Guidelines for Generalized Pustular Psoriasis Management Unveiledhttps://practicaldermatology.com/news/patient-centric-guidelines-for-generalized-pustular-psoriasis-management-unveiled/2471251/A global Delphi study has established holistic treatment goals for generalized pustular psoriasis (GPP), integrating both physician and patient perspectives. The consensus study included participants from 24 countries, and acc
- Care Urged for Adult-Onset AD Diagnoseshttps://practicaldermatology.com/news/Care-Urged-Adult-Onset-AD-Diagnoses/2471216/As revolutionary as the latest approved therapeutics for atopic dermatitis have been, Daniela Kroshinsky, MD, MPH, cautioned that dermatologists must be vigilant and consider biopsies for atypical or nonresponsive cases before starting dupilumab or a JAK inhibitor. Speaking at the Winter C
- Weight-Loss Drugs Highlighted as 'Easy' Option to Improve PsO Therapieshttps://practicaldermatology.com/news/Weight-Loss-Drugs-Highlighted-Easy-Option-Improve-PsO-Therapies/2471215/Any dermatologist not prescribing weight-loss drugs for psoriasis patients who are obese likely will be soon, according to Mark Lebwohl, MD. Dr. Lebwohl, speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, highlighted data indicating an association between como
- Dr. Armstrong Discusses Combination Therapies for Psoriasishttps://practicaldermatology.com/news/Dr-Armstrong-Discusses-Combination-Therapies-Psoriasis/2471212/The quality and variety of biologic therapeutic options available today should give dermatologists more confidence than ever in treating psoriasis, according to April Armstrong, MPH, MPH. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Armstrong discuss
- Dupixent Moves Closer to FDA Approval for Bullous Pemphigoidhttps://practicaldermatology.com/news/dupixent-moves-closer-to-fda-approval-for-bullous-pemphigoid/2471173/Dupixent® (dupilumab) significantly improved sustained disease remission in adults with bullous pemphigoid (BP) compared to placebo, according to an announcement from the manufacturers, Regeneron Pharmaceuticals and Sanofi. Acc
- 2% Medicare Payment Increase Could Be Imminenthttps://practicaldermatology.com/news/2-Medicare-Payment-Increase-Could-Be-Imminent/2471172/A 2% payment increase for physicians from Medicare appears close after American Academy of Dermatology (AAD) president Seemal Desai, MD, FAAD, attended a congressional session on February 11. “This bill has so much momentum that we are finally on the cusp,” Dr. Desai said during an AAD upd